Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization

Plus: Sanofi/GSK Restart Vaccine Trials

 
• By Scrip Team

A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.  

The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine.
Moderna is investigating the variant-targeted vaccine as a low-dose booster and in a multivalent form combining it with the authorized version. (JOSEPH PREZIOSO/AFP via Getty Images)

More from COVID-19

More from Scrip